Increased Alpha-Fetoprotein Receptor in the Serum of Patients with Early-Stage Breast Cancer

Moro, Ricardo; Tcherkassova, Janneta; Stieber, P.

doi:10.3747/co.19.979

Cited by 15 publications

(21 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since it has been suggested that RECAF, as an oncofetal protein, is expressed in large quantities in physiologic and pathologic states of high cell division and turnover rates, such as fetal development and some cancers, higher concentrations of RECAF in the PCa patients than in the benign pathology group were expected. [10][11][12][13] On the other hand, the median RECAF density was almost 1.7 times higher in the patients with PCa than in the group with benign conditions, which was a statistically significant difference. It should be noted that the median prostatic volume was almost 1.6 times lower in the malignancy group than in the benign group, possibly introducing a bias.…”

Section: Discussionmentioning

confidence: 92%

“…9,10 It has been suggested that RECAF concentrations increase in some malignant diseases (e.g., teratocarcinoma, hepatocellular, breast, lung, prostate, ovary and gastric carcinoma), whereas in benign tumors, RECAF levels do not appear elevated. [11][12][13] Moro et al studied the clinical usefulness of RECAF in the diagnostics of BPH and PCa, and they reported a sensitivity of 99% and a specificity of 95%. 11 However, no correlation to PSA concentration, histopathologic grading (Gleason grade), or the T stage of PCa was made.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Tumor marker α-fetoprotein receptor does not discriminate between benign prostatic disease and prostate cancer

Smrkolj¹,

Gubina²,

Bizjak³

et al. 2017

Adv Clin Exp Med

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 92%

mentioning

confidence: 99%

Tumor marker α-fetoprotein receptor does not discriminate between benign prostatic disease and prostate cancer

Smrkolj¹,

Gubina²,

Bizjak³

et al. 2017

Adv Clin Exp Med

View full text Add to dashboard Cite

“…Анализ полученных ранее данных по исследованию пациентов с ранними стадиями различных онкологических заболеваний [13][14][15] показал, что значительное повышение уровня N-гликопротеина СА-62 в крови пациентов, по сравнению с нормальным уровнем этого белка в сыворотке здоровых людей, напрямую связано с развитием канцероге-неза. Пороговое значение маркера СА-62 составляет 4600 Ед/мл, при этом референтный диапазон, отражающий нижнюю и верхнюю границу нормы лабораторного показателя СА-62, составляет 50-4599 Ед/мл.…”

Section: Discussionunclassified

“…Поиск высокочувствительных опухолевых маркеров, способных служить индикатором прогрессирующего роста злокачественной опухоли или, наоборот, указывать на частичный или полный ответ опухоли на лечение, не менее актуален, чем разработка новых противоопухолевых лекарственных препаратов. В качестве перспективного ClINICAl STUDIES маркера для мониторинга лечения пациентов с различными солидными опухолями был выбран инновационный раковый антиген CA-62 с M.W 62 kDa, который показал высокую чувствительность при выявлении эпителиальных злокачественных новообразований ранних стадий и получил высокую оценку экспертов в слепых исследованиях в Европе и Канаде [13][14][15].…”

Section: Introductionunclassified

A Pilot Clinical Trial to Monitor Response to Chemotherapy Using the Ca-62 Marker of Epithelial Carcinomas

Khakimova¹,

Черкасова²,

Цуркан³

et al. 2019

Sib. onkol. ž.

View full text Add to dashboard Cite

The objective of the study was to assess the feasibility of using CA -62 marker of epithelial carcinomas for monitoring treatment response and detecting cancer progression or recurrence during chemotherapy.Material and Methods. A 12-month double-blind clinical trial was conducted by two independent groups: clinical oncologists and biochemists, and involved 89 patients with different cancers confirmed by histopathological findings. The other inclusion criteria were: the presence of at least one measurable lesion according to the RECIST criteria, ECOG performance status 0-2 and satisfactory laboratory parameters. The expression of CA -62 cancer marker was measured by immunochemiluminescent assay used for the detection of epithelial carcinomas.Results. The elevated level of CA -62 marker was observed in 76 patients before starting the treatment. After completion chemotherapy, the level of this marker decreased to the normal reference ranges (<4600 U/ml) in 53 % of patients and remained increased in 24 % of patients. Of 24 % of patients with the initial low level of CA -62 marker (1000–4000 U/ml) before treatment, 12 % had no changes in the level of this marker during chemotherapy; however, 5 % of these patients had disease progression and 7 % had stable disease after starting the treatment. In 12 % of patients with an initial low CA -62 level, it increased during chemotherapy, indicating disease progression.Conclusion. The changes in the level of CA -62 marker during chemotherapy in patients with gastric cancer, small-cell lung cancer, colorectal cancer, neuroendocrine cancer and ovarian cancer showed a high correlation (76–100 % depending on the tumor site) with the performance status of the patients according to RECIST criteria. The CA -62 marker was shown to be feasible for monitoring gastric cancer, small-cell lung cancer, colorectal cancer, neuroendocrine cancer and ovarian cancer as well as for assessing the response to chemotherapy.

show abstract

“…Administration of Eruca sativa extracts resulted in a decrease in serum triglycerides, LDL, VLDL and increase of HDL-C in a contrary manner. The oncofetal antigen found in most types of cancer is the alpha-fetoprotein [53].…”

Section: Mechanism Of Cardiotoxicitymentioning

confidence: 99%

Determination of the Effects of Eruca sativa Oil, Sodium Carbonate, Lavender Oil and Aloe vera Oil on Lipid Profile and Breast Tumour Markers in Breast Cancer-induced Doxorubicin Treated Female Albino Rats

Ahmed

2020

ARRB

View full text Add to dashboard Cite

Background: Lavender oil, Eruca sativa oil and Aloe vera oil contain different types of fatty acids in addition to minerals, vitamins and other compounds which have anti-tumour action and antioxidant properties also it has cure properties against many other diseases. Sodium carbonate is alkaline material that affecting tissue PH and somewhat affecting on breast cancer through changing PH of the tissue making the medium not appropriate for breast cancer induction. Aim: Is studying the effect of Eruca sativa oil, Sodium carbonate, Lavender oil and Aloe vera oil on lipid profile, Tumor markers of breast cancer and thyroid hormones. Materials and Methods: Six groups of animals, five rats in each were used for this experiment and divided into negative control, positive control, sodium carbonate group, Eruca sativa oil group, lavender oil group and Aloe vera oil group. We induced cancer in all rats by MCF7 breast cancer cell line except negative control. Then all groups (Except positive and negative controls) were intraperitoneally (i.p.) injected with 2 mg /rat of adryadox (adryamycin chemotherapy), the remaining three groups except sodium carbonate group are supplemented with 1 ml. of the oil. Then rats are sacrificed and blood is centrifuged to obtain serum and analysis of lipid profile and breast cancer tumour markers. Results: Eruca sativa oil and Aloe vera decrease cholesterol and triglycerides, where Eruca s. oil, Lavender oil and Aloe vera oil increase HDL more than sodium carbonate, Erucas. oil, Lavender oil and Aloe vera oil decrease LDL. Eruca s. oil decrease VLDL, sodium carbonate decreases alpha-fetoprotein and Ca15-3. Conclusion and Recommendation: Based on the findings of this study, we recommend the use of lavender oil, Eruca sativa oil, Aloe vera oil and sodium carbonate administered at low doses as a helper in cure chemotherapy in treatment of breast cancer because it has useful effect in decreasing tumor markers and lipids and improve heart properties.

show abstract

Increased Alpha-Fetoprotein Receptor in the Serum of Patients with Early-Stage Breast Cancer

Cited by 15 publications

References 24 publications

Tumor marker α-fetoprotein receptor does not discriminate between benign prostatic disease and prostate cancer

Tumor marker α-fetoprotein receptor does not discriminate between benign prostatic disease and prostate cancer

A Pilot Clinical Trial to Monitor Response to Chemotherapy Using the Ca-62 Marker of Epithelial Carcinomas

Determination of the Effects of Eruca sativa Oil, Sodium Carbonate, Lavender Oil and Aloe vera Oil on Lipid Profile and Breast Tumour Markers in Breast Cancer-induced Doxorubicin Treated Female Albino Rats

Contact Info

Product

Resources

About